Offerings Now Encompass Multiplex and Parallel Analysis of Cells, Proteins, and Genes Affymetrix, best known for its pioneering work in commercializing microarrays for gene expression research since ...
Like it or not, biologists have to deal increasingly in informatics as their experiments generate ever larger and more complex data sets. Few laboratories have the resources to develop their own ...
Microarray Market Is Growing as Applications for Diagnostics and Research Are Realized Although DNA microarrays are just beginning to be investigated for diagnostics, they are becoming key tools for ...
The widely-used Affymetrix Whole-Transcript Gene 1.0 ST (sense target) microarray platform, normally used to assay gene expression, can also be utilized to interrogate exon-specific splicing. Research ...
Genomatix Software GmbH today announced that it has achieved GeneChip-compatible TM status for several products with the Affymetrix Inc. (Nasdaq: AFFX) GeneChip® microarray platform and that it has ...
SANTA CLARA, Calif.--(BUSINESS WIRE)--Affymetrix (Nasdaq:AFFX) and Ariosa Diagnostics, Inc. today announced the signing of a multi-year supply agreement covering Affymetrix arrays and instruments to ...
WASHINGTON, June 4 (Reuters) - A U.S. patent appeals court ruled on Thursday in favor of Agilent Technologies , which had been involved in a patent fight with Affymetrix Inc . The dispute was over ...
Affymetrix, Inc. (NASDAQ:AFFX) today launched the GeneChip(R) miRNA 2.0 Array. This enhanced version of its best-in-class microRNA (miRNA) interrogation solution will support the research community's ...
One of the challenges for the future is how to integrate all the DNA microarray data that have been generated and deposited in public databases. We have studied data from two data repositories and ...
Genomatix Software GmbH has announced that it has achieved GeneChip-compatible™ status for several products with the Affymetrix Inc. GeneChip ® microarray platform and that it has joined Affymetrix ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results